StockNow
Calendar
Log in
U.S. Markets

Eli Lilly (LLY) says its obesity pill, Zepbound, significantly reduced the severity of obstructive sleep apnea in patients with obesity in a late-stage trial

ORIGINAL · NewsquawkEli Lilly (LLY) says its obesity pill, Zepbound, significantly reduced the severity of obstructive sleep apnea in patients with obesity in a late-stage trial
StockNow breaking-news AI analysis

Eli Lilly reported a significant reduction in sleep apnea severity in an obesity-pill late-stage trial; the available item lacks quantitative results and trial details.

1 stocks
LLYEli Lilly & Co.$1,401.87Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Iran has reportedly dropped a demand to control the Strait of Hormuz and collect transit fees, Hayom reports citing officials; however, they are unwilling to discuss "or even signal a willingness to enter negotiations" on nuclear issues

Geopolitics

[MARKET UPDATE]: Oil prices see further pressure on reports Iraq presented proposals to end Iran war to US President Trump, who expressed his approval; knee jerk move higher in equities and T-notes see modest gains

Geopolitics

US Envoy Kushner says US President Trump is determined to bring an end to this horrible war, in relation to the Ukraine-Russia war